Beyond Ozempic: Exploring Medications and Strategies for Weight Management

Last reviewed: June 5, 2026

Last updated: June 5, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

If you started your search at Ozempic, you started one product to the left of the category you probably want. Ozempic is approved for type 2 diabetes indications and holds no weight-management claim. The approved weight-management set is Wegovy (semaglutide injection and tablets), Zepbound (tirzepatide), Saxenda (liraglutide 3 mg), Foundayo (orforglipron, approved April 1, 2026), plus older oral agents including phentermine-topiramate extended release and naltrexone-bupropion. Beyond drugs there are metabolic and bariatric procedures, and beneath all of it the lifestyle intervention every trial layered its medication onto.

The Incretin Agents

Wegovy injection carries indications for weight reduction and long-term maintenance in adults and adolescents 12 and older with obesity and in adults with overweight plus at least one comorbid condition, for cardiovascular risk reduction, and for noncirrhotic MASH with moderate to advanced fibrosis under accelerated approval. Its labeled maximum is now 7.2 mg once weekly.

Zepbound is a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist indicated for chronic weight management and, separately, for moderate to severe obstructive sleep apnea in adults with obesity. SURMOUNT-1 reported mean weight changes of −15.0%, −19.5% and −20.9% versus −3.1% with placebo over 72 weeks in 2,539 adults.

Foundayo is an oral small molecule rather than a peptide, indicated for chronic weight management in obesity or in overweight with at least one weight-related comorbid condition. Its labeling carries an explicit limitation of use against concomitant use with another GLP-1 receptor agonist.

The Non-Incretin Prescription Options

Phentermine-topiramate extended release and naltrexone-bupropion are approved oral agents for chronic weight management with substantially longer histories and different mechanisms. Orlistat acts on intestinal fat absorption rather than on appetite signalling. Phentermine alone is approved for short-term use.

These agents produce smaller mean weight reductions than the incretin class in head-to-head comparisons of trial data, but they are not interchangeable on effect size alone. Contraindication profiles differ sharply — topiramate has teratogenic risk, bupropion has seizure and psychiatric considerations, and each has its own set of populations to avoid.

Cost is the other axis. Several of these are available as generics, which changes the coverage and out-of-pocket picture substantially for someone whose plan excludes anti-obesity medications or who is paying cash.

Procedures Remain the Largest-Effect Intervention

Metabolic and bariatric surgery produces the largest and most durable weight reductions currently available, along with high rates of type 2 diabetes remission. Sleeve gastrectomy and Roux-en-Y gastric bypass are the most commonly performed procedures.

Part of the mechanism is hormonal rather than restrictive: these procedures substantially alter postprandial gut hormone secretion, including GLP-1, which is why metabolic effects can exceed what the weight change alone would predict.

Endoscopic options such as intragastric balloons occupy a middle ground with smaller effects and lower procedural risk. Whether any procedure is appropriate is a specialist assessment, and medication and surgery are increasingly used in sequence rather than as alternatives.

Why "Beyond Ozempic" Is Often a Cost Question

Many people arrive at this search because coverage was denied or the out-of-pocket price was unmanageable. If that is the situation, the most valuable single action is to establish whether your plan excludes anti-obesity medications as a benefit category at all — an exclusion cannot be appealed on clinical grounds, while a medical-necessity denial can.

Manufacturer savings and direct-purchase programs operate outside the insurance channel with their own eligibility rules, which change frequently enough to be verified with the manufacturer directly. Older generic agents are a legitimate alternative worth discussing rather than a consolation prize.

Compounded preparations are a separate cash-pay category rather than a covered alternative. They are not FDA-approved finished products, the agency does not review them for safety, effectiveness or quality before marketing, and they are not generics.

What Every Option Has in Common

Every approved weight-management indication is written as an adjunct to a reduced-calorie diet and increased physical activity, because every pivotal trial was run that way. The medication arm and the placebo arm both received the lifestyle intervention.

Protein adequacy and resistance training matter across all of these routes, because weight lost includes lean mass regardless of how it was lost. That is as true after surgery as it is on an incretin agent.

And all of them require a plan for maintenance. The Wegovy indication explicitly includes maintaining weight reduction long term, and randomised withdrawal trials across the incretin class consistently show substantial regain after discontinuation.

How to Structure the Conversation

Bring your full history: measured weight over time, prior attempts and outcomes, current medications, and every weight-related diagnosis. Bring your coverage situation. Bring a realistic monthly budget.

Ask which indication applies to you, not which brand is popular. Sleep apnea, established cardiovascular disease and MASH each map to specific approved indications, and having one of them documented changes the options available.

And ask what happens if the first choice fails or is denied. A sequence planned in advance is considerably better than restarting the search from the beginning three months later.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

What are the alternatives to Ozempic for weight loss?

Ozempic is not approved for weight loss at all — it is a type 2 diabetes product. The approved weight-management options are Wegovy (semaglutide injection and tablets), Zepbound (tirzepatide), Saxenda (liraglutide 3 mg), Foundayo (orforglipron, approved April 1, 2026), plus older oral agents including phentermine-topiramate extended release, naltrexone-bupropion and orlistat.

Is tirzepatide more effective than semaglutide?

The trial numbers are larger, but they come from separate programmes rather than a single head-to-head weight trial. SURMOUNT-1 reported mean weight changes of −15.0%, −19.5% and −20.9% versus −3.1% placebo over 72 weeks; STEP 1 reported −14.9% versus −2.4% over 68 weeks. Tolerability, contraindications, coverage and cost all bear on which is appropriate for an individual.

Are the older weight-loss pills still worth considering?

Yes, particularly when coverage is unavailable. Phentermine-topiramate extended release, naltrexone-bupropion and orlistat are approved for chronic weight management, several are available as generics, and their out-of-pocket cost is typically far lower. Mean weight reductions are smaller than with incretin agents, and each carries a distinct contraindication profile your prescriber will assess.

Where does bariatric surgery fit now?

It still produces the largest and most durable weight reductions available, with high rates of type 2 diabetes remission, partly because procedures substantially alter postprandial gut hormone secretion including GLP-1. Medication and surgery are increasingly used in sequence rather than as alternatives. Whether a procedure is appropriate is a specialist assessment.

Can I combine two GLP-1 medications for a bigger effect?

No. The approved orforglipron labeling carries an explicit limitation of use against concomitant use with another GLP-1 receptor agonist, and combining incretin agents outside a trial protocol is not supported by approved labeling. The FDA has also documented adverse events, some requiring hospitalization, associated with dosing beyond what appears in approved labels.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.